Capricor shows positive HOPE-3 results with endpoints met, regulatory uncertainty, and a strong cash runway into 2026. Find ...
-- Single Pivotal Trial Designed to Demonstrate Efficacy and Safety of Every 3- and Every 6-Month Administration in a 6-Month Treatment Period -- -- Pioneering Patient-Centric Dosing Flexibility in ...
4d
Anavex Life Sciences: Negative CHMP Decision Does Not Bode Well For Future Approval For Alzheimer's
Anavex Life Sciences' Phase 2B/3 trial failed to achieve statistical significance on both primary endpoints. Read why I ...
– Study Achieved the Primary Endpoint; Mitapivat Demonstrated a Statistically Significant Transfusion Reduction Response Compared to Placebo – – Statistical Significance Achieved for All Key Secondary ...
Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study Efdoralprin alfa demonstrated superiority in a head-to-head study versus ...
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback